Jurgi Camblong Sells 22,486 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 22,486 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.25, for a total value of $118,051.50. Following the transaction, the chairman owned 3,558,807 shares in the company, valued at approximately $18,683,736.75. This trade represents a 0.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total transaction of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total transaction of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.

SOPHiA GENETICS Trading Up 1.3%

Shares of SOPHiA GENETICS stock opened at $5.51 on Thursday. The firm’s 50 day moving average is $5.15 and its 200 day moving average is $4.97. The firm has a market capitalization of $462.23 million, a PE ratio of -10.60 and a beta of 0.96. SOPHiA GENETICS SA has a 1 year low of $2.92 and a 1 year high of $6.30. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Institutional Trading of SOPHiA GENETICS

Several institutional investors have recently added to or reduced their stakes in SOPH. Silverberg Bernstein Capital Management LLC raised its holdings in SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares during the last quarter. Green Alpha Advisors LLC boosted its stake in shares of SOPHiA GENETICS by 10.8% in the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock valued at $213,000 after purchasing an additional 4,444 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares during the period. Finally, First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth $50,000. 31.59% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SOPH has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were reported as pre-planned Rule 10b5-1 transactions tied to equity vesting and tax withholding, suggesting they may be administrative rather than a reflection of weakening business fundamentals.
• Neutral Sentiment: Several insiders sold shares in the same short period, including the chairman, CEO, CFO, and other executives, which keeps investor focus on insider activity. Article Title
• Negative Sentiment: A heavy run of insider selling can still pressure shares near term because some investors may interpret it as reduced confidence or increased stock supply.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.